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Abstract 
Background 
Multimorbidity, the coexistence of multiple health conditions, is a growing public health challenge. 
Research and intervention development are hampered by the lack of consensus regarding defining 
and measuring multimorbidity. The aim of this systematic review was to pool the findings of 
systematic reviews examining definitions and measures of multimorbidity. 
Methods 
Medline, Embase, PubMed and Cochrane were searched from database inception to February 2017. 
Two authors independently screened titles, abstracts and full texts and extracted data from the 
included papers. Disagreements were resolved with a third author. Reviews were quality assessed. 
Results  
Of six reviews, two focussed on definitions and four on measures. Multimorbidity was commonly 
defined as the presence of multiple diseases or conditions, often with a cut-off of two or more. One 
review developed a holistic definition including biopsychosocial and somatic factors as well as disease. 
Reviews recommended using measures validated for the outcome of interest. Disease counts are an 
alternative if no validated measure exists. 
Conclusions 
To enable comparison between studies and settings, researchers and practitioners should be explicit 
about their choice of definition and measure. Using a cut-off of two or more conditions as part of the 
definition is widely adopted. Measure selection should be based on tools validated for the outcome 
being considered. Where there is no validated measure, or where multiple outcomes or populations 
are being considered, disease counts are appropriate.  
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Introduction 
Multimorbidity is commonly understood to be the coexistence of multiple health conditions in an 
individual.1,2 A related term, comorbidity, describes the burden of illness co-existing with a particular 
disease of interest.3 Multimorbidity is a growing global public health challenge as populations age and 
the prevalence of long term conditions rises.1,2  
Multimorbidity is associated with poorer outcomes and the increased use of health and social care 
services with associated costs.4,5 There is increasing awareness that healthcare services are not 
adequately designed to meet the challenges of multimorbidity. Secondary care services are generally 
single disease focussed.6,7 Practitioners, particularly in primary care, face challenges in using clinical 
guidelines which are generally developed for single conditions or groups of similar conditions.8 These 
issues bring associated risks, for example polypharmacy,8,9 and challenges associated with managing 
patients with complex needs in resource limited environments.6 Multimorbidity also places a burden 
on individuals who face poorer quality of life and increased disability.10 It is highly correlated with 
frailty (an age related decline leading to reduced reserves of physical and mental health capacity, 
resulting in vulnerability to stressors and an increased risk of poor health outcomes).11,12  
Despite these challenges, there is no international consensus regarding the best way to define and 
measure multimorbidity.13 This makes carrying out and interpreting research, comparing findings 
across populations and developing guidelines and interventions difficult. A review of prevalence 
studies of multimorbidity, found estimates ranging between less than 5% to more than 95%, often 
due to differences in the operational definition of multimorbidity.2 The National Institute for Health 
and Care Excellence (NICE) recently developed a multimorbidity guideline and commented that 
measuring the prevalence of multimorbidity is complex due to the varying measures being used.14  
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A number of reviews have summarised the multimorbidity definitions or measures used in primary 
studies. Our aim was to build consensus on the most appropriate ways to define and measure 
multimorbidity by pooling the findings of these systematic reviews.   
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Methods 
The PRISMA 2009 checklist guided method development and reporting of findings.15 Medline, Embase, 
PubMed and the Cochrane database of systematic reviews were searched from database inception to 
13th February 2017. The search strategy was comparable across all databases. At the time of searching, 
there was no MeSH term for multimorbidity. The search terms relating to “multimorbidity” and its 
measures were drawn from a previous systematic review of the multimorbidity literature.16 These 
were combined by the Boolean operator “AND” with “review” as a title word. The terms were 
searched in the title only, as an initial trial search found that widening this to the abstract or full text 
significantly reduced the ability to detect relevant reviews. The search strategy is in Supplementary 
Table 1.  
Systematic reviews of the multimorbidity literature which examined multimorbidity definitions and/or 
measures as a central focus of the review were included. Whilst comorbidity is now commonly 
accepted to be distinct from multimorbidity, it is known that the terms have been used synonymously 
in the past.  Reviews of comorbidity where no specific index disease was considered were therefore 
eligible. Systematic reviews which did not have the primary aim to summarise multimorbidity 
definitions and measures were excluded. Reviews which were “narrative” or “semi-structured” or 
which otherwise were not systematic reviews were excluded. 
Title, abstract and full-text screening were carried out independently by two authors (MCJ and SWM).  
Disagreement was resolved by CB. Primary data extraction was carried out by MCJ with four others 
acting as independent second reviewers (CB, MC, GJP and SWM). The data extraction form was 
prepared and piloted by MCJ and finalised by discussion with the other reviewers.  Data extraction 
included: the review characteristics, the definition and measures of multimorbidity presented in the 
review and the rationale behind any recommended measures of multimorbidity (if given). Scottish 
Intercollegiate Guidelines Network critical appraisal checklists17 were used to assess the quality of 
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included reviews (“low quality”, “acceptable” or “high quality”). The results were combined 
narratively.  
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Results 
Figure 1 summarises the results of the search. Out of 1,051 articles sourced during the search, there 
were 432 duplicates. Following screening of titles, abstracts and full texts, six reviews were 
included.16,18-22 The characteristics of these reviews, including their stated aims, are presented in Table 
1. The Le Reste and Willadsen reviews focused on the definition of multimorbidity, whilst the 
remaining four focussed on measures. The number of studies included by the reviews ranged from 39 
to 194. Five reviews were of “acceptable quality”.16,19-22 De Groot  was “low quality” as they did not 
report the literature search strategy, the results of the literature search and the identification of 
papers clearly.18 
 
Definitions 
The multimorbidity definitions used in the included reviews are in Table 2. As described above, Le 
Reste and Willadsen were the only papers focused on reviewing definitions20,22 and so the definitions 
provided by the other four were the authors own. 
Le Reste produced a new multimorbidity definition as a result of their review:   
“…any combination of chronic disease with at least one other disease (acute or chronic) or 
biopsychosocial factor (associated or not) or somatic risk factor”.20  
Willadsen found that more than a third of studies used a cut-off of two or more conditions to define 
multimorbidity, another third did not specify any cut-off and the remainder had varying cut-off points. 
The authors found that less than a third of their included studies used an existing definition of 
multimorbidity. Additionally, definitions varied according to whether or not they specified a duration 
of condition (e.g. “occurrence in the last 5 years” or having lasted “for at least 3 months”) and whether 
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or not they specified the severity of the condition (e.g. staging of the disease). The authors state that 
consideration of whether included diseases clustered together was considered in only “a few” articles 
and there was little consideration of complications of diseases. The authors concluded that the 
majority of existing definitions are “more usable for epidemiologists than for clinicians and patients” 
and recommended the Le Reste definition due to its comprehensive nature for including more than 
just disease.22 
In the remaining reviews, De Groot and Yurkovich primarily used the term “comorbidity”.18,21 The 
consensus amongst all four was that multimorbidity is the occurrence of multiple diseases or 
conditions. Diederichs specified that multimorbidity is two or more chronic conditions.19  
 
Measures 
Commonly used measures 
Le Reste did not focus on multimorbidity measures.20 The measures covered by the remaining five 
reviews are in Table 3. Whilst the stated aim of Willadsen was to “explore how multimorbidity is 
defined in the scientific literature”, there was overlap between definitions and measures.22  
The measures included by reviews encompassed disease counts and weighted indices such as the 
Charlson Index, the Cumulative Illness Rating Scale (CIRS), the Index of Coexistent Disease (ICED), the 
Adjusted Clinical Groups (ACG) System and the Duke Severity of Illness.  
Yurkovich and Huntley examined the frequency of measures. Yurkovich categorised measures as 
“administrative data” (the most common being Charlson) and “medication-based” (the most common 
being the Chronic Disease Score).21 Huntley categorised the most common measures as: disease 
counts, the Charlson index and variations, the ACG system, the CIRS and the Duke Severity Illness 
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Check-list System.16 Despite the name, disease counts included more than just diseases (e.g. they 
included categories of conditions). The authors found disease counts being used in 98 studies and the 
number of disease “items” included within counts ranged from 9 to 35.16 Willadsen found that 
measures included by their papers contained conditions ranging in number from 4 to 147.22 
 
Recommended measures 
Yurkovich found that diagnosis based measures such as the Elixhauser index and the Romano 
adaptation of the Charlson index were best able to predict mortality outcomes whist the medication 
based Chronic Disease Score, was best able to predict health care use.21 Huntley recommended that 
researchers select a measure for a study based upon the measure validated for use in that scenario, 
for example, the Charlson index for predicting mortality. The authors also state that simple counts of 
diseases or medications perform almost as well as complex measures in predicting most outcomes.16  
De Groot assessed the content, criterion and construct validity of measures. They concluded that the 
Charlson, CIRS, ICED and Kaplan indices are valid and reliable methods for use in clinical research but 
that other measures (such as disease counts) were more difficult to assess due to limited data.18  
Willadsen did not recommend a single measure and instead, as described previously, stated the 
importance of including risk factors, symptoms and severity of diseases.22 Diederichs also did not 
recommend a single measure. They found studies of disease counts often did not specify the criteria 
for the selection of diseases, but if criteria were given these were: high prevalence of the disease, 
using other indices as a reference point for the selection of disease, or high impact conditions in terms 
of increased mortality risk, an impact on function and health and the need for management.  They 
recommended 11 conditions selected on the basis of being the most common causes of inpatient and 
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outpatient attendance as well as death in people aged over 64 in Germany. The conditions included 
cancer, depression, myocardial infarction and hypertension.19 
 
Data sources 
All five reviews found patient self-report, physician reports, clinical examinations, medical record 
reviews and administrative data (‘coded databases’ or ‘routine data’) were common sources of 
multimorbidity data amongst their included studies.16,18,19,21,22 No review studied whether any source 
was superior, although Yurkovich found evidence that the Charlson index derived from self-report and 
that derived from administrative data had similar abilities to “predict various outcomes”.21 De Groot  
stated that medical chart reviews are preferable for use in smaller studies as they likely yield the most 
complete data but that this is likely impractical in larger studies and so administrative databases can 
be used.18 Similarly, Huntley noted that administrative data have the advantage of ease of use but 
may be limited by data quality issues.16 
  
12 
 
 
Discussion 
Summary of findings 
Our review pooled the findings of six systematic reviews. We found heterogeneity of multimorbidity 
definitions and measures but there were a number of commonalities.  
Most reviews defined multimorbidity as the occurrence of multiple diseases or conditions, the most 
common cut-off being two or more. Le Reste produced a new definition which encompassed 
biopsychosocial factors and somatic risk factors along with disease.20 This was recommended by 
Willadsen as being the most clinically relevant definition of multimorbidity available.22  
Common measures included the Charlson, CIRS, ICED, Kaplan, the ACG system and disease counts, 
with advice that measures be selected based upon the purpose of a particular study.16,18 No reviews 
made recommendations about the most appropriate data sources to use when measuring 
multimorbidity. 
 
Strengths and limitations  
Our systematic review provides a high-level summary of both the definition and measurement of 
multimorbidity in relevant systematic reviews. Ours is the first to focus upon those reviews which 
primarily aimed to examine multimorbidity definitions or measures. This is important given the 
heterogeneity in definitions and measures available and the associated complexity in developing 
consensus. We acknowledge that reviews such as that by Fortin et al (of prevalence studies of 
multimorbidity)2 and Marengoni et al (of ageing and multimorbidity)5 discuss recommended 
definitions and measures at the end of their reviews but we have not included these as their primary 
aim did not meet our inclusion criteria.  
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A limitation is that search terms were limited to the title only for practical reasons which means some 
relevant reviews could be missed.  We conducted a test search including these terms in the abstract 
or full text which revealed no additional reviews in the first 100 titles screened. Additionally, as 
recommended by PRISMA, systematic reviews should be identified as such in the title. 15 
One of the included reviews (examining measures of multimorbidity) was classed as low quality. 
However, as there were three other reviews examining multimorbidity measures this should reduce 
the likelihood that this affected our findings.  
 
Comparison with literature 
Our findings are consistent with other systematic reviewers who have encountered challenges due to 
the lack of common approach towards measuring and defining multimorbidity.2,23-25   
 
Definitions 
Willadsen highlighted that many definitions and measures seem to be tailored towards use in research 
rather than being clinically relevant.22 It is true that traditional approaches, for example measuring 
multimorbidity using the Charlson or disease counts, do not capture the holistic experience of 
multimorbidity. For example, we know that an individuals’ ability to cope with disease is influenced 
by both person factors and wider socio-environmental factors and that at a population level, 
multimorbidity is associated with higher levels of deprivation.4,26-30 The definition by Le Reste is more 
likely to capture this complexity but the multi-faceted nature of the definition makes it difficult to 
operationalise in practice.  Instead of adding further elements to the definition and measurement of 
multimorbidity, it is perhaps more appropriate to ensure there is consideration of its holistic nature 
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when studying its determinants and outcomes and when managing it clinically. This would include 
understanding its relationship with health inequalities in areas of high deprivation, as well as to frailty 
and the ageing process.11,12 
The cut-off point regarding the minimum number of conditions to equate to being multimorbid needs 
further consideration. The most common cut-off point found by our reviews was two or more 
conditions and this was consistent with the findings of Fortin in their review of prevalence studies of 
multimorbidity.2 The prevalence of multimorbidity is inevitably affected by the cut-off selected and 
additionally it is likely that a higher cut-off would select a patient group with a higher burden of 
multimorbidity.2 This needs further research, for example by testing the number of conditions which 
best identify patients at higher risk of outcomes such as hospital stay, disability, frailty or mortality.  
 
Measures 
When multimorbidity is defined and measured on the basis of a count of conditions the measurement 
of multimorbidity is closely linked to the definition. We have used the term “disease counts” as this is 
the common phrase used in the literature, but acknowledge these measures can include a wider 
spectrum of health conditions (for example risk factors for disease). Disease counts are likely more 
appropriate for scenarios where multiple outcomes are being considered or in which no single 
weighted measure has been validated.16 They may also be a more intuitive summary of multimorbidity 
burden in patients, for example when showing the link between multimorbidity and socioeconomic 
status.4 Additionally, reviews have found that multimorbidity may be more appropriately considered 
as different common clusters of conditions and this is easier to measure using counts.24,31 If 
researchers are selecting conditions to include in a count the purpose of the work being conducted 
must be considered. Some conditions, for example depression, may have greater impact upon patients 
15 
 
 
in terms of quality of life or function.32 Other conditions such as heart disease may impact more upon 
health services in terms of number of admissions or treatment costs.2,19 
In studies using weighted measures the definition and measurement of multimorbidity are more 
distinct. Many weighted measures were originally developed as comorbidity measures but are 
increasingly being used as multimorbidity measures.18 Weighted measures, if used for appropriate 
outcomes, can assist in predicting patient outcome and future healthcare usage and can also provide 
an assessment of the burden of multimorbidity experienced by the patient, their carers or health and 
social care services.33 Therefore, where the aim is to examine outcomes in patients and to account for 
the presence of multiple conditions, a validated weighted measure may be more appropriate or 
informative than a disease count.  
Data sources 
No review recommended a particular data source to measure multimorbidity. In the wider literature, 
a number of studies and reviews have compared data sources for comorbidity and multimorbidity 
measures, often with conflicting findings.3,34 The availability of data and the resource implications will 
additionally affect the choice of data used. For example, whilst case-note review is viewed as being 
more complete than administrative data it is more resource intensive.3,34 Another important data 
source is patient self-report, which may be more likely to capture conditions which may not be seen 
as important clinically but impact on function or quality of life.32  Regardless of measure, different data 
sources will affect the prevalence of multimorbidity.2,35  
Implications for research and practice 
Our key recommendation is that researchers be explicit about the definitions and measure(s) they are 
using and give a rationale for their choice. This will enable comparison of findings across different 
16 
 
 
settings and outcomes as well as progress the evidence base regarding the most appropriate 
definitions and measures for particular scenarios. 
Multimorbidity is an important public health challenge, which is influenced strongly by wider social 
and environmental factors. In this review, the paper by Le Reste highlighted the holistic nature of 
multimorbidity.20 In clinical and public health practice, holistic approaches which take into account 
more than just the medical management of disease could assist with reducing its impact. However, 
there is a need for more evidence on the effectiveness of primary care and community based 
interventions, including those tackling the challenges experienced by individuals with socio-economic 
deprivation.36 Despite this, recent research in primary care in deprived areas has shown that a co-
development model of intervention development for multimorbidity (CARE Plus) was feasible and may 
be cost-effective, thus pointing to future directions in reducing the burden of multimorbidity.37,38  
Overall, a definition of multiple co-existing conditions is reasonable and a cut-off should be explicitly 
defined. Researchers would be consistent with others by using a cut-off of two or more. Using a 
weighted measure validated for the outcome being considered is advised, but where evidence is weak 
or where multiple outcomes or populations are being considered, the use of disease counts is 
appropriate. There is precedence for the inclusion of conditions other than solely chronic disease in a 
multimorbidity measure but a rationale for included and excluded conditions should be given. 
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Key points 
 To improve consensus in defining and measuring multimorbidity we recommend researchers 
and practitioners be explicit about the definitions and measure(s) they are using and give a 
rationale for their choice. 
 We conclude that multimorbidity is the coexistence of multiple conditions (most commonly 
defined as two or more conditions).  
 Validated multimorbidity measures for particular scenarios should be chosen if these exist. 
Where there is no validated measure or where multiple outcomes or populations are being 
considered, disease counts are appropriate. 
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Tables and Figures 
Table 1: Characteristics of included reviews 
Review 
reference 
Stated Aim of the review Databases and dates 
of search undertaken 
by the review 
Total titles / 
abstracts 
screened 
Total texts included Quality 
assessment* 
De Groot 
et al, 
200318  
'Which methods are available for measuring 
comorbidity that can be used in RCTs and prognostic 
studies' 
Medline: January 1966 
to September 2000. 
Embase: January 1988 
to September 2000. 
Not reported Not reported Low quality 
Diederichs 
et al, 
201119 
‘Multimorbidity, defined as the coexistence of 2 or 
more chronic diseases, is a common phenomenon 
especially in older people. Numerous efforts to 
establish a standardized instrument to assess the level 
of multimorbidity have failed until now, and indices 
are primarily characterized by their high 
heterogeneity. Thus, the objective is to provide a 
comprehensive overview on existing instruments on 
the basis of a systematic literature review.’ 
Medline: January 1, 
1960 to August 31, 
2009 
1120 39 
 
Acceptable 
Huntley et 
al, 2012 16 
‘The aims of this review were (1) to identify and 
describe measures of multimorbidity that are most 
suitable for use in research in primary care and 
community populations, taking into account the data 
and resources they require, and (2) to investigate the 
validity of these measures in terms of whether they 
have demonstrated anticipated associations with 
patient characteristics, process measures, and health 
outcomes.’ 
Medline and Embase:  
database inception to 
December 2009 
11191 194 
 
Acceptable 
23 
 
 
Le Reste et 
al, 2013 20 
‘What are the criteria for multimorbidity found in the 
scientific medical literature and what definition could 
be produced with these criteria?’ 
 
PubMed, Embase and 
Cochrane: January 1, 
1990 to December 31, 
2010. 
416 54 Acceptable 
Yurkovich 
et al, 
201521 
‘To conduct a systematic review of studies reporting 
on the development or validation of comorbidity 
indices using administrative health data and compare 
their ability to predict outcomes related to 
comorbidity (i.e., construct validity).’ 
Medline and Embase: 
1946 to September 
2012 
955 76 Acceptable  
Willadsen 
et al, 
201622 
‘Objective is to explore how multimorbidity is defined 
in the scientific literature, with a focus on the roles of 
diseases, risk factors, and symptoms in the definitions.’ 
PubMed, Medline and 
Embase: inception to 
October, 4, 2013. 
Cochrane database: 
inception to 
October,10, 2013 
943 163 Acceptable  
Abbreviations: SIGN, Scottish Intercollegiate Guidelines Netwok; RCT, randomised controlled trial 
* Based upon SIGN categories  
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Table 2: Multimorbidity definitions from included reviews 
Review reference Definition given a priori* or 
as a result of evidence review 
Definition 
De Groot et al, 
200318  
a priori  ‘the co-occurrence of multiple chronic or acute diseases and medical conditions in one person’  
Diederichs et al, 
201119 
a priori  ‘Multimorbidity describes “the coexistence of two or more chronic diseases” in the same 
individual.’ 
Huntley et al, 2012 14 a priori  ‘the co-occurrence of multiple diseases or medical conditions within 1 person.’ 
Le Reste et al, 201320 Review of evidence ‘Multimorbidity is defined as any combination of chronic disease with at least one other disease 
(acute or chronic) or biopsychosocial factor (associated or not) or somatic risk factor. Any 
biopsychosocial factor, any somatic risk factor, the social network, the burden of diseases, the 
health care consumption, and the patient’s coping strategies may function as modifiers (of the 
effects of multimorbidity). Multimorbidity may modify the health outcomes and lead to an 
increased disability or a decreased quality of life or frailty.’ 
Yurkovich et al, 
201521 
a priori This review used the definition of comorbidity:  
‘Comorbidity may be defined as the total burden of illnesses unrelated to the principal 
diagnosis’ 
Willadsen et al, 
201622 
Review of evidence  Provides no single definition. 
Conclusion: 
-Existing definitions (consisting mainly of diseases) are ‘more usable for epidemiologists than for 
clinicians and patients’. 
-Recommends definition by Le Reste et al (above) 
* a priori indicates this is the reviewers own definition 
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Table 3: Multimorbidity measures, conditions and data sources recommended by included review 
Review 
reference 
Measures included MM measure 
recommended? 
Rationale for MM 
measure 
recommended 
Specific MM 
conditions 
recommended? 
MM data sources recommended? 
De Groot 
et al, 
200318  
Disease counts and 12 
weighted measures 
(Burden of disease index, 
Charlson index, CIRS, 
Cornoni-Huntley index, 
Duke Severity of Illness 
index 
Hallstrom index, Hurwitz 
index, ICED, Incalzi index, 
Kaplan index, Lui index 
Shwartz index) 
 
Concludes Charlson, 
CIRS, ICED and Kaplan 
are valid and reliable 
methods to measure 
comorbidity in clinical 
research. 
 
Validity and 
reliability 
No No specific recommendation. 
 
-  Commonly used methods to obtain 
data in included studies: ‘interviews, 
questionnaires, physical examinations, 
medical chart reviews and coded 
databases’. 
Diederich
s et al, 
201119 
Weighted indices:  
Charlson Index, 
Comorbidity Symptom 
Scale, Seattle Index of 
Comorbidity, 
Medication-Based 
Disease Burden Index, 
KoMo Score, Index of 
Coexisting Diseases, 
Functional Comorbidity 
Index, Incalzi Index, 
Kaplan-Feinstein Index, 
Physiologic Index of 
Comorbidity, Geriatric 
Index of Comorbidity, 
Self-Administered 
Recommends a 
disease count of 11 
conditions.  
 
Found most studies 
did not specify 
criteria for selection 
of diseases. If criteria 
given: high 
prevalence of the 
disease, using other 
indices as a reference 
point for the 
selection of disease, 
conditions which are 
associated with an 
Disease count 
based on 
conditions which 
are the 20 most 
frequently listed 
diagnoses for 
people aged 
greater than or 
equal to 65 years 
in three data 
sources in 
Germany (the 
inpatient sector, 
the outpatient 
sector and 
Cancer, diabetes, 
depression, 
hypertension, MI, 
chronic ischaemic 
heart disease, heart 
arrythmias, heart 
insufficiency, stroke, 
COPD, arthritis.  
No specific recommendation. 
 
- Included studies used: patient self-
report, physician reports, clinical 
examinations, medical records, and 
administrative data. 
 
- Gives advice on self-report: 'use disease 
specifications that can be distinguishable 
by lay persons [in order to increase 
validity of self-report]. 
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Comorbidity 
Questionnaire, Shwartz 
Index and Chronic 
Disease Score.  
increased mortality 
risk, conditions 
associated with 
impact on function 
and health and the 
need for 
management. 
mortality 
statistics). 
Huntley 
et al, 
2012 16 
Disease counts and 
weighted measures.  
 
Most common measures 
(n studies): disease 
count (98), Charlson 
(38), ACG System (25), 
CIRS (10), Duke Severity 
of Illness (6). 
1. Care utilisation:  
the ACG System, 
Charlson index, or 
disease counts  
2. Costs: 
The ACG System  
3. Mortality: 
Charlson index 
4. Quality of life: 
Disease counts or 
Charlson index  
5. Other outcomes: 
Simple counts of 
diseases or 
medications 
Recommendations 
based upon 
purpose of study 
and evidence base 
behind measures 
used for that 
purpose. 
  
No  No specific recommendation. 
 
- Commonly used measures: interviews, 
questionnaires, physical examinations, 
medical chart reviews, and coded 
databases. 
 
 
Yurkovich 
et al, 
201521 
Administrative data 
measures (n studies): 
Charlson and its 
adaptations (35); 
Elixhauser (2); Fleming et 
al. index (1); Abildstrom 
et al. index (1) 
 
Medication- based 
indices:  
Diagnosis-based 
measures, 
(particularly 
Elixhauser and the 
Romano adaptation 
of the Charlson) 
resulted in higher 
ability to predict 
mortality outcomes.  
 
Recommends 
selection of 
measure to be 
based on ‘type of 
data available, the 
study population, 
and the specific 
outcome of 
interest in the 
study.’ 
No No specific recommendation. 
 
Review was limited to administrative data 
indices only but the authors commented 
on included studies which compared data 
sources (all were Charlson studies): 
- two studies found self-report and 
administrative data had similar ability to 
‘predict various outcomes’ 
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Chronic Disease Score 
(9), Rx-Risk (3) and 
Medication Based 
Disease Burden Index (2) 
 
 
Medication-based 
indices, (such as the 
Chronic Disease 
Score) demonstrated 
better performance 
for predicting health 
care utilization. 
-One review and two studies found poor 
agreement between case note review 
and administrative data 
 
Willadsen 
et al, 
201622 
Charlson, Clinical 
Classification Software, 
CIRS, ACG, Aggregated 
Diagnosis Groups, 
Medication based, 
Expanded Diagnosis 
Clusters, Resource 
Utilization Bands, The 
Functional Comorbidity 
Index, ICED, QoF, The 
Registration Network 
Family Practices 
Does not recommend 
a single measure. 
As documented in 
Table 2, the authors 
state the importance 
of including risk 
factors and 
symptoms and 
severity as well as 
diseases if want a 
clinically relevant 
definition (and thus 
measure) 
N/A No No specific recommendation. 
 
The included studies used data from 
administrative data and self-report 
Abbreviations: MM, multimorbidity; CIRS, Cumulative illness rating scale; ICED, Index of Coexistent disease; MI, myocardial infarction; COPD, chronic 
obstructive pulmonary disease; ACG, Adjusted Clinical Groups; QoF, Quality Outcomes Framework; N/A, not applicable 
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Figure 1: Flow-chart of search strategy 
 
Databases searched  
1051 references: 
Medline: 403, Embase: 625, PubMed: 22 (one year history only to 
detect work not yet on Medline and Embase); Cochrane: 1 
(although did not include “review” as title word, included as 
classed by Cochrane as a systematic review). 
 
432 duplicates removed. 
619 titles screened 
Excluded 580:  
479 not on topic; 3 foreign language text, 98 conference 
abstracts. 
24 full texts screened  
Excluded 18:  
16 not on topic, 1 unable to access, 1 unable to find in 
original journal at given reference. 
6 reviews included 
39 abstracts screened 
Excluded 15:  
10 not systematic reviews, 4 focus is comorbidity, 1 further 
duplicate. 
